Publications scientifiques

Raynal S, Foucault AS, Ben Massoud S, Dioh W, Lafont R, Veillet S, 2015. BIO101, a drug candidate targeting sarcopenic obesity through Mas receptor activation. Journal of Cachexia, Sarcopenia and Muscle 2015; 6: 429 (

Acuña MJ, Pessina P, Olguin H, et al. 2014. Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-ß signalling. Human Molecular Genetics, doi: 10.1093/hmg/ddt514. Riquelme C, Acuña MJ, Torrejón J, Rebolledo D, Cabrera D, Santos RA, Brandan E. 2014. ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis. PLoS One, 9(4): e93449. (

Foucault AS, Even P, Lafont R, Dioh W, Veillet S, Tom. D, Huneau JF, Hermier D, Quignard- Boulangé A. 2014. Quinoa extract enriched in 20-hydroxyecdysone affects energy homeostasis and intestinal fat absorption in mice fed a high-fat diet. Physiol Behav 128: 226-231. (

Tirupula KC, Desnoyer R, Speth RC, Karnik SS. 2014. Atypical signaling and functional desensitization response of mas receptor to peptide ligands.PLoS ONE, 9(7): e103520. (

Wuttke W, Seidlova-Wuttke D. 2013. Pflanzliche Präparate füt die Therapie klimaterischer und postmenopausaler Beschwerden und Erkrankungen. Frauenartz 54(6): 580-587.

Aussel C, Woelffle E, Lemoigne P, Depailler L, Bouillanne O. 2013. Une nouvelle stratégie nutritionnelle pour lutter contre la dénutrition et la sacopénie : le régime protéique pulsé. Cahiers Nutrition Diététique, 48: 33-40. (

Yoshida T, Tabony AM, Galvez S, Mitch WE, Higashi Y, Sukhanov S, Delafontaine P. 2013. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia. Int J Biochem Cell Biol, 45: 2322-2332. (

Ma F, Yang Y, Li X, Zhou F, Gao C, Li M, Gao L. 2013. The association of sport performance with ACE and ACTN3 genetic polymorphism: a systematic review and meta-analysis. PLoS One, 8(1): e54685. (

Smith RC, Lin BK. 2013. Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care, 7: 352-360. (

Foucault AS, Mathé V, Lafont R, Even P, Dioh W, Veillet S, Tom. D, Huneau D, Hermier D, Quignard-Boulangé A. 2012. Quinoa extract enriched in 20-hydroxyecdysone protects mice from diet- induced obesity and modulates adipokines expression. Obesity 20: 270-277. (

Buford TW, Manini TM, Hsu FC, Cesari M, Anton SD et al. 2012. Angiotensin-converting enzyme inhibitor use by older adults is associated with greater functional reponses to exercise. J Am Geriatr Soc, 60(7): 1244-1252. (

Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD. 2012. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomopathy in Duchenne muscular distrophy. Am J Cardiol, 10: 98-102. (

Brotto M, Abreu EL. 2012. Sarcopenia : Pharmacology of today and yomorrow. J Pharmacol Exp Ther 343(3): 540-546. (

Jarosz PA, Bellar A. 2011. Sarcopenic obesity : an emerging cause of frailty in older adults. Geriatric Nursing, 30(1): 64-70. (

Kim TN, Park MS, Yang SJ, Yoo HJ, Kang HJ, Song W, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. 2010. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes. Diabetes Care 33: 1497-1499. (

Gorelick-Feldman J, Cohick W, Raskin I. 2010. Ecdysteroids elicit a rapid Ca2+ flux leading to Akt activation and increased protein synthesis in skeletal muscle cells. Steroids 70: 632-637. (

Scime A, Caron AZ, Grenier G. 2009. Advances in myogenic cell transplantation and skeletal muscle tissue engineering. Frontiers in Bioscience, 14: 3012-3023. (

Lynch GS, Ryall JG. 2008. Role of -adrenoreceptor signaling in skeletal muscle : implications for muscle wasting and disease. Physiol Rev, 88: 729-767. (

Zamboni M, Mazzali G, Fantin F, Rossi A, Di Francesco V. 2008. Sarcopenic obesity: a new category of obesity in the elderly. Nutrition, Metabolism & Cardiovascular Diseases 18: 388-395 (

Carter CS, Groban L. 2008. Role of the renin-angiotensin system in age-related sarcopenia and diastolic dysfunction. Aging Health, 4(1): 37-46. (

Sumukadas D, Witham MD, Struthers AD, McMurdo MET. 2007. Effect of perindopril on physical function in elderly people with functional impairment : a randomized controlled trial. CMAJ, 177(8): 867-874. (

Symons TB, Schutzler SE, Cocke TL, Chinkes DL, Wolfe RR, Paddon-Jones D. 2007. Aging does not impair the anabolic response to a protein-rich meal. Am J Clin Nutr, 86: 451-456. (

Walrand S, Boirie Y. 2007. Obésité sarcopénique: “parle à mon gras, mon muscle est malade. Obésité 2: 331-338. (

Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR. 2006. A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly. Am J Physiol Endocrinol Metab, 291: E381-387. (

Di Nari M, van de Poll-Franse LV, Onder G, Kritchevsky SB, Newman A, Harris TB et al. 2004. Antihypertensive medications and differences in muscle mass in older persons : the health, aging and body composition study. J Am Geriatr Soc, 52(6): 961-966. (

Anker SD, Negassa A, Coats AJS, Afzal R, Poole-Wilson PA, Cohn JN et al. 2003. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin- converting-enzyme inhibitors: an observational study. Lancet, 361(9363): 1077-1083. (

Onder G, Penninx BWJH, Balkrishnan R, Fried LP, Chavez PHM, Williamson J et al. 2002. Relation between use of angiotensine-converting enzyme inhibitors and muscle strength and physical function in older women : an observational study. Lancet, 359(9310) : 926-930. (

Hébuterne X, Bermon S, Schneider SM. 2001. Ageing and muscle: the effects of malnutrition, re- nutrition, anfd physical exercise. Curr Opin Clin Nutr Metab Care, 4(4: 295-300. (

Pupim LB, Heimbürger O, Qureshi AR, Ikizler TA, Stenvinkel P. Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int, 68(5): 2368-2374. (

Nazarov IB, Woods DR, Montgomery HE, Shneider OV, Kazakov VI, Tomilin NV, Rogozkin VA. 2001. The angiotensin converting enzyme I/D polymorphism in Russian athletes. Eur J Hum Genet, 9(10): 797-801. (

Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE, Delafontaine P. 2001. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth-factor I. Endocrinology, 142(4): 1489-1496. (

Wu X, Lin J, Liang Z, Shi F. 2001. Beneficial effects of ecdysterone on rat myocardial infarction induced by coronary occlusion. Zhongcaoyao (Chinese traditional and herbal Drugs) 32(8): 721-723.

Azizov AP, Seifulla RD, Ankudinova IA, Kondrat’eva II, Borisova IG. 1998. Effect of the antioxidants elton and leveton on the physical work capacity of athletes. Eksp Klin Farmakol 61(1): 60-62.

Gadzhieva RM, Portugalov SN, Paniushkin VV, Kondrat’eva II. 1995. A comparative study of the anabolic action of ecdysten, leveton and Prime Plus, preparations of plant origin. Eksp Klin Farmakol 58(5): 46-48.

Fiatarone MA, O’Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME, Roberts SB, Kehayias JJ, Lipsitz LA, Evans WJ. 1994. Exercise training and nutritional supplementatino for physical frailty in very elderly people. J Medicine, 330(25): 1769-1775. (

Simakin SYu, Panyushkin VV, Portugalov SN, Kostina LV, Martisorov EG. 1988. Combined application of preparation Ecdysten and product Bodrost during training in cyclic sports. Sports Science Bulletin N°2, 29-31.